Innatoss Laboratories (https://apc01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.innatoss.com%2Fen%2F&data=02%7C01%7CBerkan.Unal%40genscript.com%7C82302e2804b6462badcb08d85b% 7Cdc65b2eb97864a0e9fed90b43a77c777% 7C1% 7C0% 7C637359715791846676 & sdata = 7ai9fkIhS942pqqTsd1q6yNWE4% 2BZf1s1rcneAbf14j0% in Europe announced the tests against the 2 nd blanket for the general public against the gene service. 2 SARS .protection.outlook.com /? url = http% 3A% 2F% 2F% 2Fwww.genscript.com & data = 02% 7C01% 7CBerkan.Unal% 40genscript.com% 7C82302e2804b6462badcb08d85b48dd1f% 7Cdc65b2eb97864a0e9fed90b43a77c777% 7C1% 7C0% 7C637359715791856667 & sdata = FZpi02rLZILAgCfjz7df7oI% 2BuSPLYlUCDq43HOJ5YpE% 3D & reserved = 0) cPass SARS-CoV-2 detection kit for neutralizing antibodies (https://apc01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genscript.com%2Fcovid-19-detection- svnt.html & data = 02% 7C01% 7CBerkan.Unal% 40genscript.com% 7C82302 e2804b6462badcb08d85b48dd1f% 7Cdc65b2eb97864a0e9fed90b43a77c777% 7C1% 7C0% 7C637359715791856667 & sdata = ofeqFYiPzSzkmQQrWv97WthxoX is used. The test kit is the first worldwide that enables the rapid detection of neutralizing antibodies (NAbs); these NAbs are found in the serum of COVID-19 patients and are responsible for warding off the virus infection. Innatoss is the first medical laboratory in Europe to offer such a service to the general public.
“Our collaboration with GenScript is a critical step in bringing high quality, innovative products to market to combat the COVID-19 pandemic, which is a global public health threat,” said Dr. Anja Garritsen, CEO of Innatoss. “cPass uses a novel test method that can detect the presence of virus-specific neutralizing antibodies. The test would also be conceivable to determine the duration of potential immunity in individuals and thus in the general population, thus also determining the development of vaccines and monoclonal antibody therapies The test will become an important indicator for monitoring neutralizing antibody titers in the blood of individuals once vaccination is given. ”
A study recently carried out by Innatoss in the southern Dutch city of Kessel, which was hit hard by the first wave of COVID-19, determined the lifespan of binding antibodies compared to neutralizing antibodies in test subjects. The patients’ IgG and IgM levels were initially determined using a rapid test 2-4 months after infection and then repeated again 2-3 months later. The patient samples were then tested for neutralizing antibodies using the GenScript cPass kit. In 90 percent of the cases, binding antibody levels fell significantly over time, while functional antibodies (neutralizing antibodies) remained constant in 70 percent of the tests.
“The cPass test achieves reliable results that correspond to the gold standard in virology laboratories, the ‘Live SARS-CoV-2 Virus Neutralization Test’, without the need for a biosafety level 3 laboratory,” explained Dr. Linfa Wang, the inventor of cPass and director of the Emerging Infectious Disease Program at Duke-NUS Medical School in Singapore. “This novel test not only shows the individual’s history of infection, it can also provide information on how we can protect ourselves in the future.”
“This collaboration is a significant step forward as it provides valuable insights into potential immunity and gives institutions around the world better access to a reliable COVID-19 testing approach,” said Dr. Patrick Liu, CEO of GenScript.
About GenScript Biotech Corporation
GenScript Biotech Corporation is a global biotechnology group that applies its proprietary technologies in a variety of areas: from fundamental research in the life sciences to translational biomedical research to industrial synthetic products and cell therapy solutions. With its goal of improving the health of humans and nature through biotechnology, the company has developed first-class capacities and competencies for the production of biological reagents and active ingredients.
About Innatoss Laboratories
Innatoss is a research-focused diagnostics laboratory in the Netherlands that combines product development with performing cutting-edge diagnostics for individuals and the community. With its core competence in serology and T-cell biology, it covers all aspects of the immune response in infectious diseases. Innatoss focuses on infectious diseases with a complex immunological background such as Q fever and Lyme disease. The company’s mission to “recognize early! … and significantly reduce health problems associated with infectious diseases” has been expanded to include COVID-19 in view of the 2020 epidemic.
Logo – https://mma.prnewswire.com/media/1274339/Logo_Logo.jpg
GenScript Biotech Corporation
Media Susan Thomas
Original content by: GenScript, transmitted by news aktuell
Original message: https://www.presseportal.de/pm/148417/4710951